Flex downsizing on troubles with sole clinical program

Flex Pharma Inc. (NASDAQ:FLKS) said it is cutting headcount by about 60% after discovering its sole clinical program, FLX-787, will require additional work that stretch beyond the biotech's

Read the full 289 word article

User Sign In